Consensus ORIC Pharmaceuticals, Inc.

Stocks

ORIC

US68622P1093

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 00:00:00 07/08/2026 +04			5-day change	1st Jan Change
12.93 ^USD	0.00%		+14.63%	+58.07%

08-04	ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-15	ORIC Pharmaceuticals Starts Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer	MT

Evolution of the Average Target: ORIC Pharmaceuticals, Inc.

Evolution of the Target Price: ORIC Pharmaceuticals, Inc.

Changes in Analyst Recommendations: ORIC Pharmaceuticals, Inc.

f68c551097824a30.7xMcRFOkd0-RF_ILe_52Ovx2FUVcYi2lOYSjwwWtjzg.hiVzBwqVIRWiLpNNNL9AdqoRYi8KPRXWDbSWi1Cb_lO1TG4QBfYeJ-RugQ~6ff147e74cf7910595228db113aab8f5

Analysts' recommendations: ORIC Pharmaceuticals, Inc.

04-01	Wedbush Cuts Price Target on ORIC Pharmaceuticals to $17 From $20, Keeps Outperform Rating	MT
01-07	Piper Sandler Initiates ORIC Pharmaceuticals Inc at Overweight With $22 Price Target	MT
11-14	Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $15 From $12, Maintains Outperform Rating	MT
06/05/25	Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $12 From $15, Maintains Outperform Rating	MT
31/10/24	JonesTrading Initiates ORIC Pharmaceuticals at Buy With $17 Price Target	MT
31/10/24	Wells Fargo Initiates ORIC Pharmaceuticals at Overweight With $20 Price Target	MT
06/09/24	Stifel Nicolaus Initiates Coverage on ORIC Pharmaceuticals With Buy Rating, $20 Price Target	MT
13/08/24	Oppenheimer Adjusts ORIC Pharmaceuticals Price Target to $15 From $17, Maintains Outperform Rating	MT
27/03/24	JPMorgan Trims ORIC Pharmaceuticals' Price Target to $18 From $19, Maintains Overweight Rating	MT
21/03/24	HC Wainwright Adjusts ORIC Pharmaceuticals' Price Target to $21 From $15, Keeps Buy Rating	MT
12/03/24	Baird Cuts Price Target on ORIC Pharmaceuticals to $25 From $27, Maintains Outperform Rating	MT
01/03/24	Wedbush Adjusts Oric Pharmaceuticals' Price Target to $20 From $12, Maintains Outperform Rating	MT
26/02/24	Cantor Fitzgerald Initiates ORIC Pharmaceuticals at Overweight Rating	MT
13/12/23	HC Wainwright Trims Price Target on ORIC Pharmaceuticals to $15 From $16, Keeps Buy Rating	MT
12/12/23	Wedbush Lowers ORIC Pharmaceuticals' PT to $12 From $14, Pushes Out Launch Assumption for ORIC-533; Keeps Outperform Rating	MT
26/10/23	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $16 From $13, Maintains Buy Rating	MT
24/10/23	JPMorgan Adjusts ORIC Pharmaceuticals' Price Target to $17 From $14, Maintains Overweight Rating	MT
23/10/23	Citigroup Adjusts ORIC Pharmaceuticals' Price Target to $15 From $13, Maintains Buy Rating	MT
22/09/23	Wedbush Starts ORIC Pharmaceuticals at Outperform With $14 PT, Says Expanding Pipeline Provides Future Potential Growth Opportunities	MT
16/08/23	Baird Adjusts Price Target on ORIC Pharmaceuticals to $27 From $15, Keeps Outperform Rating	MT
15/08/23	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $13 From $14, Keeps Buy Rating	MT
10/05/23	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $14 From $16, Keeps Buy Rating	MT
05/04/23	Citigroup Adjusts Price Target on ORIC Pharmaceuticals to $8 From $9, Maintains Buy Rating	MT
23/03/23	HC Wainwright Upgrades ORIC Pharmaceuticals to Buy From Neutral, Price Target is $16	MT
21/03/23	Guggenheim Upgrades ORIC Pharmaceuticals to Buy From Neutral, Price Target is $15	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ORIC PHARMACEUTICALS, INC.					+61.22%
	WUXI APPTEC CO., LTD.					+17.53%
	ARGENX SE					+19.92%
	BIONTECH SE					+30.81%
	INSMED INCORPORATED					+97.89%
	WUXI BIOLOGICS (CAYMAN) INC.					+16.16%
	GENMAB A/S					+26.43%
	PHARMAESSENTIA CORPORATION					-19.6%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+15.31%
	EXELIXIS, INC.					-7.85%
	Average					+25.78%
	Weighted average by Cap.					+22.81%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.93USD

Average target price

20.85USD

Spread / Average Target

+61.22%

High Price Target

25.00USD

Spread / Highest target

+93.35%

Low Price Target

14.00USD

Spread / Lowest Target

+8.28%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Wedbush
Piper Sandler
Oppenheimer
Wells Fargo Securities
JonesTrading Institutional Services
JPMorgan Chase
HC Wainwright
Baird
Cantor Fitzgerald
Citigroup
Guggenheim